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a b s t r a c t
Introduction: Obstructive sleep apnea (OSA) is considered as a risk factor for the development
and worsening of compensation of arterial hypertension and other cardiovascular diseases.
Prevalence of masked and nocturnal hypertension can have a signiﬁcant negative impact on
these patients and these prevalences are not well known.
Aim: To evaluate the prevalence of masked and nocturnal hypertension in patients with
OSA.
Materials and methods: In this study, 97 (88 men) patients were enrolled, average age 53.9
 9.7 years. OSA was diagnosed with polysomnography and the continuous positive airway
pressure therapy has been indicated according to current guidelines. Then were evaluated
parameters of OSA (apnea-hypopnea index (AHI), oxygen desaturation index (ODI), % of
sleep time <90% SpO ,2  average night SpO ).2  Patients also underwent physical examination
including ofﬁce blood pressure measurement, 24 h blood pressure monitoring (ABPM) and
measurement of anthropometric parameters.
Results: Following average values were present in OSA patients (mean value and standard
deviation): AHI 54.6  22.7, ODI 58.3  24, % of sleep time < 90% SpO 35.42   25.1, average
night SpO 88.82   5. Masked hypertension was present in 55 (56.7%) patients, nocturnal
hypertension in 79 (81.4%) patients. Arterial hypertension was appropriately compensated
in only 15 (15.5%) patients. Results have not shown any statistically signiﬁcant correlation
between prevalence of nocturnal hypertension and AHI ( p = 0.059), % of sleep time <90%
SpO (2  p = 0.516), average night SpO (2  p = 0.167). ODI was signiﬁcantly higher in patients with
nocturnal hypertension ( p = 0.002). No correlation between prevalence of masked hyper-
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Conclusion: This study has demonstrated high prevalence of masked and nocturnal hyper-
tension in patients with OSA, which can considerably increase risks of cardiovascular
diseases in these patients.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
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.Introduction
Obstructive sleep apnea (OSA) is a common chronic disorder
and its clinical presentation has been well known for many
centuries. In 330 AD Claudius Aelianusensus described typical
signs of OSA in the king of Portus, whose servants had to
awake him with needles to avoid choking. Prevalence of this
disorder is described in 2–4% of middle aged individuals [1].
Common signs are snoring with apneic and hypopneic pauses
and frequent micro arousals [2]. Consequences are distur-
bance of sleep architecture and repeated awakening, which
can be accompanied by insomnia, nocturnal polyuria and dry
mouth. Patients suffer from poor quality of sleep and
pronounced tiredness. Increased sleepiness occurs during
daytime and mainly while performing monotone activities.
Concentration and memory are worsening, depression and
sexual dysfunctions could also occur [3].
Nowadays, this syndrome is considered as a risk factor for
development of cardiovascular and metabolic disorders such
as ischemic heart disease, arterial hypertension, diabetes
mellitus, heart conductance abnormalities and cerebrovascu-
lar disorders [4–6]. Nevertheless, only a limited number of
physicians are evaluating sleep disorders – in our pilot study
only 13% of all physicians treating patients with heart
arrhythmias were directly asking patients about this syn-
drome. Same situation can be expected in other groups of high
risk patients [6].
Relationship between OSA and arterial hypertension is
under intensive evaluation because arterial hypertension
doubles the risk of cardiovascular diseases (including myocar-
dial infarction), congestive heart failure, ischemic and hemor-
rhagic stroke, renal failure and diseases of peripheral arteries
[7].
Arterial hypertension is present in approximately 50% of
patients with OSA. In comparison, the common prevalence of
arterial hypertension in population of same patients without
OSA is 30% [8]. OSA is increasing the risk of arterial
hypertension independently on other factors – Sleep Heart
Health Study showed linear correlation between systolic and
diastolic blood pressure level and severity of OSA [9]. In these
patients, arterial hypertension is present mostly during night
and it has a form of so called non-dipper type (blood pressure
level during nighttime is the same or higher than during the
day) [5,10]. In patients with resistant arterial hypertension,
OSA is present in up to 83% of patients [11]. From these ﬁndings
emerges the fact that in all patients with resistant arterial
hypertension (patients taking combination of at least three
antihypertensive drugs, one of which is a diuretic) OSA should
be excluded.Masked hypertension (MH) is deﬁned as a blood pressure
which is higher during home measurement-24 h blood
pressure monitoring (ABPM) or self monitoring) than casual
blood pressure level measured in an ofﬁce [12]. Prevalence of
masked hypertension in general population is estimated to be
10–25% [13–15]. An arbitrary threshold of masked hyperten-
sion was deﬁned as blood pressure >135/85 mmHg measured
by ABPM during daytime [13]. Mere assessment of blood level
pressure during the day does not detect nocturnal hyperten-
sion which then remains unrecognized. The prevalence of
cardiovascular complications in patients with MH is twice as
high as in common population and MH is signiﬁcantly under
diagnosed [16]. In previous years, only few studies have
evaluated the prevalence of MH in patients with OSA [17,18].
Common ﬁnding of these studies is the fact that prevalence of
MH is higher in OSA patients in comparison with general
population.
The aim of this study was to assess the prevalence of
masked and nocturnal hypertension in patients with OSA
indicated for continuous positive airway pressure therapy
according to current guidelines and to evaluate their depen-
dency on parameters of OSA.
Materials and methods
97 patients (88 male) were enrolled in this study, average age
53.9  9.7 years. We included consecutively examined patients
from Sleep laboratory of Department of Respiratory Medicine,
Palacky University and University Hospital Olomouc with
diagnosis of OSA (using polysomnography (Alice 5, Respiro-
nics, USA)) who were indicated for continuous positive airway
pressure therapy (CPAP) (apnea-hypopnea index >15). Out of
included patients, 84 had a history of previously treated
arterial hypertension and they were treated with substances
from all of main pharmacotherapeutical classes of antihyper-
tensive drugs. Then we evaluated parameters of OSA: apnea-
hypopnea index (AHI), oxygen desaturation index (ODI),
average night SpO2 a % of sleep time <90% SpO2. Than we
performed physical examination including blood pressure (BP)
measurement (standard sphygmomanometer, average of
second and third measurement as a result), according to
guidelines arterial hypertension threshold was deﬁned as 140/
90 mmHg. Later we measured following parameters: body
mass index (BMI-patient's weight (kg)/height (m)2), waist and
hip circumference and Epworth sleepiness scale.
Following exclusion criteria were applied in this study:
ejection fraction <50%, signiﬁcant heart valve disorder,
diagnosed cause of secondary arterial hypertension other
than OSA, pulmonary ﬁbrosis, chronic obstructive pulmonary
Table 2 – Average office and ambulatory blood pressure
levels.
BP (n = 97) ø  SD
Ofﬁce BP (mmHg) Systolic BP 135.4  13.5
Diastolic BP 82.4  10.7
ABPM mBP (mmHg) 24 h Systolic BP 136.4  13.3
Diastolic BP 80.3  8.6
Day Systolic BP 139.7  13.5
Diastolic BP 83.3  9.2
Night Systolic BP 131.9  15.4
Diastolic BP 75.8  9.7
Table 3 – Correct BP compensation and prevalence of
masked/nocturnal hypertension (n = 97).
N %
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patients with central sleep apnea, patients with low compli-
ance and patients taking medication that could interfere with
parameters followed in this study.
We also performed ambulatory blood pressure monitoring
(ABPM) using Spacelabs (Spacelabs Healthcare) device. Fol-
lowing arbitrary values were deﬁned as targets: mean
measured blood pressure (mBP) 130/80 mmHg for 24-h
interval; mBP 135/85 mmHg during daytime and mBP 120/
70 mmHg during night [19]. Patient meets diagnostic criteria
for masked/nocturnal hypertension when he/she presents
normal ofﬁce BP together with abnormal result from
whichever of above mentioned BP intervals (systolic and also
diastolic BP).
For requirements of this study two deﬁnitions of masked
hypertension were chosen.
D I. Normal ofﬁce BP together with abnormal mBP according
to ABPM in whichever measured interval.
D II. Normal ofﬁce BP together with abnormal mBP
according to ABPM measured during daytime.
Two deﬁnitions of masked hypertension were chosen to
help us evaluate changes in prevalence of MH when taking
nocturnal hypertension into account.
Nocturnal hypertension (NH) was deﬁned as mBP during
night >120/70 mmHg irrespective of blood pressure level
measured in ofﬁce.
White coat syndrome was deﬁned as an abnormal ofﬁce BP
together with normal mBP measured by ABPM.
Correct BP compensation was deﬁned as an ofﬁce BP <140/
90 mmHg and all mBP measured by ABPM in normal range.
This study obtained all necessary institutionary review
board approvals with conduction of this research.
Data were analyzed using SPSS version 15 (SPSS Inc.,
Chicago, USA). The normality of data was tested using the
Shapiro–Wilk test. Statistical evaluation was carried out using
Student's t test and the Mann–Whitney U test at signiﬁcance
level of 0.05.
Results
Basic clinical parameters are shown in Table 1.
Average ofﬁce blood pressure and ambulatory blood
pressure monitoring results are shown in Table 2.Table 1 – Basic clinical parameters.
Basic clinical parameters Sample (n = 97) ø  SD
Male 85
Female 12
Age 53.9  9.8
Apnea-hypopnea index 54.6  22.8
Oxygen desaturation index 58.3  24
Average night SpO2 (%) 88.8  5
% of sleep <90% SpO2 35.4  25.1
Epworth sleepiness scale 10.3  5.1
Body mass index 37.9  19.2Table 3 shows number and percentage of patients with
correct blood pressure compensation (ofﬁce blood pressure
(<140/90 mmHg) or ABPM (mBP <130/80 mmHg during 24 h;
<135/85 mmHg during daytime and <120/70 mmHg during
night)) together with prevalence of masked hypertension
(according to deﬁnition I, II), nocturnal hypertension (mBP
>120/70 mmHg) and white coat syndrome.
Correct BP compensation measured by ABPM was present
in only 15 (15.5%) of patients.
MH-deﬁnition I was present in 55 patients (56.7%) from the
whole sample (97 patients), which represents 82.1% of patients
with correct ofﬁce BP level (67 patients). MH-deﬁnition II was
present in 41 (42.3%) of patients from the whole sample (97
patients), which represents 61.2% of patients with normal
ofﬁce BP level (67 patients). Nocturnal hypertension was
present in 79 (81.4%) of the whole sample (97 patients).
Prevalence of MH and NH was correlated with parameters
of OSA. Student's t-test did not show signiﬁcant correlation
between prevalence of nocturnal hypertension and AHI
( p = 0.059), % of sleep <90% SpO2 ( p = 0.516), average night
SpO2 ( p = 0.167). ODI was signiﬁcantly higher in patients with
nocturnal hypertension in comparison with patients without
this entity ( p = 0.002).
Student's two-sample t-test did not show correlation
between prevalence of masked hypertension and AHI
( p = 0.841) and ODI ( p = 0.137) and using Mann Whitney U
test we did not found correlation between prevalence of MH
and average night SpO2 ( p = 0.991) and % of sleep <90% SpO2
( p = 0.896).Ofﬁce BP compensation 67 69.1
24 hour systolic + diastolic BP compensation 26 26.8
24 hour systolic BP compensation 30 30.9
24 hour diastolic BP compensation 46 47.4
Daytime systolic + diastolic BP compensation 33 34.0
Daytime systolic BP compensation 35 36.1
Daytime diastolic BP compensation 56 57.7
Night systolic + diastolic BP compensation 18 18.5
Night systolic BP compensation 23 23.7
Night diastolic BP compensation 31 32.0
BP compensation according to ABPM 15 15.5
Masked hypertension-D I 55 56.7
Masked hypertension-D II 41 42.3
Nocturnal hypertension 79 81.4
White coat syndrome 3 3.1
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Only a limited number of studies of prevalence of MH in
patients with OSA exist. The probable reason is that if a
patient presents normal ofﬁce BP, hardly any physician
performs ABPM. This is the case even if masked hypertension
is increasing patient's cardiovascular risk [16]. Recent ERS/
ESH guidelines for management of patients with obstructive
sleep apnea and hypertension [20] do not mention prevalence
of MH in OSA patients, and only recommend usage of ABPM or
home monitoring devices for more accurate diagnostic of MH
or NH.
For purpose of our study, we have intentionally chosen
patients with moderate to severe OSA with indication for CPAP
treatment. Probably because of this selection has our study
found very high prevalence of masked hypertension in
patients with OSA. MH was initially present in 55 (56.7%) of
patients (when we used more strict criteria which included
nocturnal hypertension) and in 42% of patients (when we uses
criteria which took into consideration only mBP during
daytime). In studies published by Drager et al. [17,21] and
Baquet et al. [18] (who were evaluating prevalence of masked
hypertension according to less strict deﬁnition), was preva-
lence of MH 39% and 30%. In the ﬁrst case this prevalence was
the same as in our study, in two other studies the prevalence of
MH was slightly lower. This could be attributed to the selection
of patients, e.g. Drager et al. [21] included only patients without
antihypertensive treatment. When we compare our results
with available literature, we can hypothesize, that in patients
with more severe OSA, MH and NH are more prevalent. Based
on these results, more large scale studies including subjects
from whole spectrum of patients with OSA and arterial
hypertension are needed.
In our study we used common criteria and also more strict
criteria (D I) for MH. This is well justiﬁed in patients with OSA
because of the high prevalence of nocturnal hypertension in
these patients.
In the available literature we have not found any studies
correlating the prevalence of MH with parameters of OSA.
Prevalence of nocturnal hypertension was very high in
these patients – 81.4%. This ﬁnding is consistent with
previously published data [10]. The correlation between AHI
and the prevalence of nocturnal hypertension was close to
reach statistical signiﬁcance. Also in patients with nocturnal
hypertension was ODI signiﬁcantly higher. This could present
evidence for higher importance of oxygen desaturation in
pathophysiology of development of nocturnal hypertension
than the simple presence of apneic and hypopneic pauses [22].
For better understanding of pathophysiology of nocturnal
hypertension development, more studies with sufﬁcient
sample size are needed.
The mechanism how could OSA lead to development of
masked hypertension is unknown. This effect could mediated
by increased tone of sympathetic nervous system [23],
dysregulation of renin–angiotensin–aldosterone system [24]
and by endothelial dysfunction [25]. Only a limited number of
studies of how OSA inﬂuences masked/nocturnal hyperten-
sion exist and nowadays, though there is no consensus about
pathophysiological mechanisms of their development. One ofpossible explanations is a hypothesis, that even minimal
stimulus leads to a development of arterial hypertension
because of autonomic nervous system dysregulation.
There is not enough evidence on how to treat these
patients. Only one study of the inﬂuence of continuous
positive airway pressure therapy on prevalence of masked
hypertension has been published. Drager et al. described
reduction of MH prevalence in patients treated with CPAP
[17]. Limitations of this study are the short-term treatment
of patients (only 3 months) and the small sample size- only
18 patients were enrolled in this study. There is a need to
conduct more studies in the future to enlighten this
problem.
Because of the signiﬁcant prevalence of MH in patients with
OSA, we have to consider if it would be beneﬁcial to include
ABPM into polysomnographic devices. This is supported by the
fact that recent ESH guidelines [16] recommend that ABPM
usage improves sensitivity of prediction of serious cardiovas-
cular events. Using this algorithm we would be able to
diagnose arterial hypertension together with OSA and thus
save resources needed for future evaluation of patients and
improve their comfort and compliance. Baquet et al. [18]
recommended usage of ABPM to identify MH when casual
systolic and diastolic pressure are above 125/83 mmHg
(positive predictive value >90%). Together with CPAP therapy
we could concomitantly start more effective antihypertensive
treatment.
One of limitations of this study is the enrollment of patients
with cardiometabolic comorbidities, such as known and
treated arterial hypertension, diabetes or ischemic heart
disease and obesity. However, with this approach we were
able to create a sample of patients that most closely reﬂects
composition of patients referred to the sleep laboratory. Other
limitation is an absence of control group of patients with
identical age, gender and BMI without sleep disordered
breathing, In the future, we plan to perform more studies,
which will also include control group.
Conclusion
This study has shown high prevalence of masked and
nocturnal hypertension in patients with OSA indicated for
CPAP treatment. Unrecognized hypertension (even during
daytime or night) increases the patient's risk of cardiovascular
diseases. Because of these facts it is necessary to perform
ABPM in all patients with OSA. Only with this approach we
would be able to recognize arterial hypertension which could
worsen prognosis of these patients.
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